Sarepta Therapeutics Announces Tentative FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular Dystrophy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Roth Capital Reiterates Buy on Sarepta Therapeutics (SRPT) as Advisory Meeting Set for January 22nd
October 15, 2015 9:52 AM EDTRoth Capital reiterated a Buy rating and $50.00 price target on Sarepta Therapeutic (NASDAQ: SRPT) as the advisory meeting has been set for January 22nd.
Analyst Debjit Chattopadhyay commented, "The PDUFA remains February 26th, 2016, but the delayed committee meeting has handed the bears a new... More
AdCom Changes Gives Sarepta Therapeutic (SRPT) Prep Time; Recommends Owning Into Briefing Doc Release
October 15, 2015 8:00 AM EDTOppenheimer analyst Christopher Marai reiterated an Outperform rating and $45 price target on Sarepta Therapeutic (NASDAQ: SRPT) saying the January 22 Eteplirsen review gives the company more prep time. The analyst recommends owning the stock into drisapersen's briefing document release.
Marai commented, "Oct. 14, 2015, the FDA... More
Sarepta Therapeutics (SRPT) Announces Tentative Scheduling of FDA Review for Eteplirsen in DMD
October 14, 2015 12:44 PM EDTSarepta Therapeutics (NASDAQ: SRPT) announced the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is tentatively scheduled to review Sareptas New Drug Application (NDA) for eteplirsen, for the treatment of Duchenne muscular dystrophy (DMD) amenable to... More
